Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Risedronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 12/20 | 0.97 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.97 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | GGPS1 | O95749 | 2/20 | 0.49 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Risedronic Acid SCHEMBL22720092 | 0.98 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL18378 | 0.98 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL29362587 | 0.98 | FDPS (1.00) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3771017 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4989214 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL2115054 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL3170751 | 0.97 | FDPS (0.97) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL22720090 | 0.95 | FDPS (0.94) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| Risedronic Acid SCHEMBL4643040 | 0.90 | FDPS (0.83) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 | |
| SCHEMBL10001488 | 0.89 | FDPS (0.82) | FDPSBTN3A1PDE3ACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050260272-A1 | Method of forming microparticles that include a bisphosphonate and a polymer | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2005-11-24 | — | — | US | claimed |
| WO-2005107714-A2 | METHOD OF FORMING MICROPARTICLES THAT INCLUDE A BISPHOSPHONATE AND A POLYMER | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20120128780-A1 | NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS | ELAN PHARMA INTERNATIONAL LTD. | 2012-05-24 | — | — | US | disclosed |
| US-8158153-B2 | Nanoparticulate bisphosphonate compositions | ALKERMES PHARMA IRELAND LIMITED (IE) | 2012-04-17 | — | — | US | disclosed |
| EP-1476451-B1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMA (IL) | 2010-03-17 | — | — | EP | disclosed |
| US-20090209763-A1 | Novel Process For Making Bisphosphonic Acids Using Diluents Other Than Halogenated Hydrocarbons | LIDOR-HADAS RAMI | 2009-08-20 | — | — | US | disclosed |
| WO-2008020305-A2 | SOLID DOSAGE FORMS OF BISPHOSPHONIC ACIDS | AUROBINDO PHARMA LIMITED (IN) | 2008-02-21 | — | — | WO | disclosed |
| US-20060210639-A1 | Nanoparticulate bisphosphonate compositions | ELAN PHARMA INTERNATIONAL LIMITED | 2006-09-21 | — | — | US | disclosed |
| US-7038083-B2 | Process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2006-05-02 | — | — | US | disclosed |
| US-20050260272-A1 | Method of forming microparticles that include a bisphosphonate and a polymer | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2005-11-24 | — | — | US | disclosed |
| WO-2005107714-A2 | METHOD OF FORMING MICROPARTICLES THAT INCLUDE A BISPHOSPHONATE AND A POLYMER | ALKERMES CONTROLLED THERAPEUTICS, INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| EP-1476451-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-17 | — | — | EP | disclosed |
| US-20040043967-A1 | Novel process for making bisphosphonic acids using diluents other than halogenated hydrocarbons | TEVA PHARMACEUTICALS USA, INC. | 2004-03-04 | — | — | US | disclosed |
| WO-2003097655-A1 | USE OF CERTAIN DILUENTS FOR MAKING BISPHOSPHONIC ACIDS | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2003-11-27 | — | — | WO | disclosed |
| WO-1993013801-A1 | TREATMENT FOR ATHEROSCLEROSIS | THE PROCTER & GAMBLE COMPANY (US) | 1993-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120128780-A1 | NANOPARTICULATE BISPHOSPHONATE COMPOSITIONS | ACP3, BPGM, SOST | FDPS 204/4885BTN3A1 540/4885PDE3A 2306/4885 |
| US-20060210639-A1 | Nanoparticulate bisphosphonate compositions | ACP3, BPGM, SOST | FDPS 204/4885BTN3A1 540/4885PDE3A 2306/4885 |
| US-20050260272-A1 | Method of forming microparticles that include a bisphosphonate and a polymer | PHOSPHO1, PTH1R, SOST | FDPS 300/4885BTN3A1 2912/4885PDE3A 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.